Tango Therapeutics

Curated news coverage, institutional background, regulatory filings, and investigative reporting across RDU Global.

8 Stories Indexed

Last Updated: Just Now

Verified Entity Intelligence

Global Markets & Equities 25 Oct 2026, 08:00 AM IST

Tango Reports 82% Tumor Response in Pancreatic Cancer Trial, Raising the Stakes in a Crowded Race

Tango Therapeutics said its combination therapy produced an 82% tumor response rate in an early-stage trial involving advanced pancreatic cancer, a result that could sharpen investor attention on one of oncology’s most difficult targets. The data add momentum to the company’s strategy, while also inviting scrutiny over durability, patient selection and whether the response can translate into a meaningful late-stage commercial opportunity.

By RDU Global Wire5 min read

India Entertainment & Culture8h ago

Begum Akhtar Reimagined Through Dastangoi in Bengaluru, Tracing Heartbreak, Agency and Song

A Bengaluru performance of Dastan-e-Akhtari brought Begum Akhtar's life into sharp relief through storytelling, live music and a fresh reading of her choices. Narrator Kafeel Jafri and singer Yusra Naqvi used the centuries-old Dastangoi form to explore the ghazal legend not as a tragic figure, but as a woman navigating respectability, love, rebellion and artistic freedom.

5 min readRead →

Healthcare, Pharma & Life SciencesJust now (09:37 AM IST)

Dastan-e-Akhtari Recasts Begum Akhtar as a Voice of Memory, Loss and Defiance

A recent Dastangoi performance in Bengaluru, Dastan-e-Akhtari, revisited the life and art of Begum Akhtar through spoken narrative, music and cultural memory. The production framed the legendary ghazal and thumri singer not just as a performer of heartbreak, but as an artist who turned private pain into a public language of elegance and resistance.

5 min readRead →

Startups & Venture CapitalJust now (02:02 PM IST)

Beam Therapeutics Sues Chinese Biotech and VC-Backed Startup Over Alleged IP Theft

Beam Therapeutics has filed suit against a Chinese biotech company and a venture-capital-backed startup, alleging theft of intellectual property tied to its gene-editing technology, according to STAT. The case adds to mounting tensions over biotech innovation, cross-border technology transfer, and the protection of proprietary research in a sector where patents and trade secrets are central to valuation.

6 min readRead →

Global Health & Biotech06 Oct 2026, 08:29 AM IST

AstraZeneca CEO Says Summit Drug Could Anchor Next Wave of Cancer Combinations After $2 Billion Bet

AstraZeneca Chief Executive Pascal Soriot said Summit Therapeutics’ cancer drug could become a foundation for the next generation of combination therapies, underscoring why the Anglo-Swedish drugmaker has committed about $2 billion to the biotech. The comments come as AstraZeneca and Daiichi Sankyo move to test Summit’s ivonescimab alongside Datroway, a sign that large pharmaceutical groups are racing to secure the most promising assets in oncology.

5 min readRead →

Clean Energy & Climate Transition04 Oct 2026, 08:22 AM IST

Poxvirus Study Reveals a Human Gene It Has Kept and Repurposed for Survival

Scientists have identified a poxvirus carrying a stolen human gene and, unusually, showing signs that it has retained and refined the genetic material over time rather than discarding it. The finding offers a rare window into how viruses can borrow from their hosts and adapt those genes for their own biology, with implications for virology, evolutionary research, and the design of future therapeutics.

5 min readRead →

Global Health & BiotechJust now (03:00 PM IST)

Foghorn Cuts 40% of Staff After Lilly Ends Cancer Pact on Data Concerns

Foghorn Therapeutics is laying off about 40% of its workforce after Eli Lilly terminated a cancer drug collaboration that had been a key strategic and financial pillar for the biotech company. The collapse of the partnership, reportedly tied to concerns over data quality, has intensified pressure on Foghorn’s pipeline and sent its shares sharply lower as investors reassess the company’s near-term prospects.

5 min readRead →

Markets, IPOs & Wealth16 Oct 2026, 11:52 AM IST

Sensors, 3D-Printed Skin and Wearables Set Up a New Health-Tech Market

A new wave of healthcare technology is moving from the lab into commercial markets, with sensors, wearables, 3D-printed skin, reconstructed organs and personalized medicine reshaping how care is delivered and financed. The shift is creating fresh opportunities for investors, IPO candidates and listed medtech firms as clinical trials, diagnostics and treatment models become more data-driven and patient-specific.

5 min readRead →

🏢 About this Entity

Corporations, startups, regulatory bodies, central banks, ministries and judicial courts. All news mentioning this entity is automatically verified and aggregated into this live intelligence dossier.

Co-Occurring Entities

Entities frequently referenced alongside Tango Therapeutics:

Washington, D.C.(1)Revolution Medicines(1)